Andrew D. Cherniack
机构：Broad Institute, Harvard University, Dana-Farber Cancer Institute · ORCID：0000-0003-0470-0111
发表论文 1099 篇 · 总被引 127150 次 · h-index 119
代表论文
- A compendium of next-generation patient-derived models for diverse cancers (2026 · Nature · 被引 3)
- Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer (2026 · npj Precision Oncology · 被引 3)
- Supplementary Methods 1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer (2026 · 被引 1)
- Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models (2026 · Journal of Clinical Investigation)
- Figure S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer (2026)
- Table S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer (2026)